Biorestorative Therapies (BRTX)
(Delayed Data from NSDQ)
$1.45 USD
+0.02 (1.40%)
Updated Aug 8, 2025 03:59 PM ET
After-Market: $1.44 -0.01 (-0.69%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
BRTX 1.45 +0.02(1.40%)
Will BRTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BRTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BRTX
Zymeworks Inc. (ZYME) Tops Q2 Earnings and Revenue Estimates
Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Lags Revenue Estimates
BRTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Biorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Lags Revenue Estimates
Stoke Therapeutics, Inc. (STOK) Tops Q1 Earnings and Revenue Estimates
Coherus BioSciences (CHRS) Reports Q1 Loss, Lags Revenue Estimates
Other News for BRTX
BioRestorative Therapies to Report Second Quarter 2025 Financial Results and Host Conference ...
BioRestorative to Participate in Benzinga All-Access Show Today to Discuss Compelling BRTX-100 ...
BioRestorative Therapies (BRTX) Initiates $2 Million Stock Buyback Program | BRTX Stock News
BioRestorative Announces Share Repurchase Program | BRTX Stock News
BioRestorative Therapies announces share repurchase program; shares gain over 8%